QuidelOrtho Corporation’s shares were trading at $27.39 on July 25th, with trailing and forward P/E ratios of 9.16 and 11.22. The company is seen as a growing diagnostics franchise trading at a deep discount due to pandemic-related revenue distortions and integration challenges. Under new CEO Brian Blaser, operational discipline is being restored, and margins are expanding.

Quidel’s acquisition of Ortho Clinical Diagnostics brought a laboratory diagnostics business with strong organic growth potential. Recent results show organic growth in laboratories and point-of-care segments, along with margin expansion. The company aims for annual EBITDA expansion and free cash flow conversion exceeding 50% by 2028.

The stock is down 30% due to unfounded fears of Chinese tariffs, offering a potential 2026E FCF yield of 13-14%. With a conservative 10x 2028E EBITDA multiple, the share price could triple. Catalysts like margin expansion and deleveraging create an attractive risk/reward profile for investors. Novana sees QuidelOrtho as a strong investment opportunity amid its operational turnaround.

Read more at Yahoo Finance: QuidelOrtho Corporation (QDEL): A Bull Case Theory